Analyzing Spruce Biosciences (SPRB) and Its Competitors

Spruce Biosciences (NASDAQ:SPRB) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Spruce Biosciences to related businesses based on the strength of its dividends, risk, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Spruce Biosciences and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	0	11	0	2.83
Spruce Biosciences Competitors	9834	15121	45433	1587	2.54

Spruce Biosciences currently has a consensus target price of $158.33, indicating a potential upside of 240.14%. As a group, “Biotechnology” companies have a potential upside of 102.19%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than its peers.

Valuation and Earnings

This table compares Spruce Biosciences and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	N/A	-$38.97 million	-1.17
Spruce Biosciences Competitors	$719.20 million	$12.16 million	-15.01

Spruce Biosciences’ peers have higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Spruce Biosciences has a beta of 3.57, suggesting that its share price is 257% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Spruce Biosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Spruce Biosciences Competitors	-12,357.18%	-197.96%	-30.56%

Institutional & Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats its peers on 8 of the 13 factors compared.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.